These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
47. IMPACT OF LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ON PREEXISTING MICROSTRUCTURAL ALTERATIONS IN DIABETIC MACULAR EDEMA. Wirth MA; Wons J; Freiberg FJ; Becker MD; Michels S Retina; 2018 Sep; 38(9):1824-1829. PubMed ID: 28767550 [TBL] [Abstract][Full Text] [Related]
48. Central retinal vein occlusion: modifying current treatment protocols. Ashraf M; Souka AA; Singh RP Eye (Lond); 2016 Apr; 30(4):505-14. PubMed ID: 26869163 [TBL] [Abstract][Full Text] [Related]
49. Characteristics and Outcomes of Full-thickness Macular Hole Repair in Patients Receiving Anti-VEGF Injections for Neovascular Age-related Macular Degeneration. Ringeisen AL; Parke DW; Dev S Int Ophthalmol Clin; 2019; 59(1):127-135. PubMed ID: 30585922 [No Abstract] [Full Text] [Related]
50. [Prospects and Challenges of Anti-VEGF Drug Treatment for Pathological Angiogenesis of the Retina]. Nakamura S; Hara H Yakugaku Zasshi; 2021; 141(12):1307-1317. PubMed ID: 34853203 [TBL] [Abstract][Full Text] [Related]
51. [Design of the ORCA module in the OCEAN study : Evaluation of SD-OCT results in daily routine practice]. Heimes B; Schick T; Brinkmann CK; Wiedon A; Haegele B; Kirchhof B; Holz FG; Pauleikhoff D; Ziemssen F; Liakopoulos S; Spital G; Schmitz-Valckenberg S Ophthalmologe; 2016 Jul; 113(7):570-80. PubMed ID: 26868827 [TBL] [Abstract][Full Text] [Related]
52. Diabetic macular edema. Lang GE Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122 [TBL] [Abstract][Full Text] [Related]
53. Aflibercept: an update on recent milestones achieved. Palejwala NV; Lauer AK Drugs Today (Barc); 2014 Dec; 50(12):779-90. PubMed ID: 25588083 [TBL] [Abstract][Full Text] [Related]
54. [New drug VEGF Trap-Eye--Eylea--and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia]. Rejdak R; Szkaradek M; Taslaq W; Kałuzny JJ; Grieb P; Jünemann AG Klin Oczna; 2012; 114(4):308-10. PubMed ID: 23461161 [TBL] [Abstract][Full Text] [Related]
55. Systemic Safety of Prolonged Monthly Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema: A Systematic Review and Meta-analysis. Avery RL; Gordon GM JAMA Ophthalmol; 2016 Jan; 134(1):21-9. PubMed ID: 26513684 [TBL] [Abstract][Full Text] [Related]
56. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA. Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940 [TBL] [Abstract][Full Text] [Related]
58. INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX). Houston SK; Rayess N; Cohen MN; Ho AC; Regillo CD Retina; 2015 Sep; 35(9):1757-64. PubMed ID: 26110596 [TBL] [Abstract][Full Text] [Related]
59. One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema. Schwarzer P; Ebneter A; Munk M; Wolf S; Zinkernagel MS Ophthalmologica; 2019; 241(4):220-225. PubMed ID: 30654365 [TBL] [Abstract][Full Text] [Related]
60. Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naïve patients with retinal vein occlusion and macular edema: a 12-month follow-up study. Chiquet C; Dupuy C; Bron AM; Aptel F; Straub M; Isaico R; Romanet JP; Creuzot-Garcher C Graefes Arch Clin Exp Ophthalmol; 2015 Dec; 253(12):2095-102. PubMed ID: 25673251 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]